4.1. Analysis.

Comparison 4 UPDRS ADL section (Part II), Outcome 1 UPDRS ADL section (Part II).

UPDRS ADL section (Part II)
Study	Placebo	Entacapone	Tolcapone (50mg)	Tolcapone (100mg)	Tolcapone (200mg)	Tolcapone (400mg)
Entacapone
Brooks UK‐IRISH 2003	Placebo n = 57	Entacapone n = 115; not significant
Myllyla FILOMEN 2001	'On' state. Placebo n = 93	Entacapone n = 182, P<0.001
Poewe CELOMEN 2002	'On' state. Placebo n = 88	Entacapone n= 172, P<0.05 (95% CI ‐2.46; ‐0.02)
PSG SEESAW 1997	'On' state. Placebo n= 102	Entacapone n=103; P=0.03
Rinne NOMECOMT 1998	Placebo n = 86	Entacapone n = 85; P<0.01
Tolcapone (all doses)
Adler TFSGIII 1998	Placebo n=72, least‐squares mean = ‐0.7 (SD 3.4)			Tolcapone 100mg n=69, least squares mean = ‐0.4 (SD 3.3); not significant	Tolcapone 200mg n=74, least‐squares mean =‐0.5 (SD 3.4); not significant
Baas 1997	Placebo n=58 (no data available)			Tolcapone 100mg n=60 (no data available); not significant	Tolcapone 200mg n=59 (no data available); not significant
Dupont TIPSII 1997	'On' state. Placebo least‐squares mean = 0.4 (SD 2.3)				Tolcapone 200mg n=32 least‐squares mean = 1.1 (SD 2.3); p<0.05	Tolcapone 400mg n=32, least square mean = 0.1 (SD 2.3); not significant
Myllyla TIPS1 1997	'On' state. Placebo least‐squares mean = ‐0.8 (SD 3.0)		Tolcapone 50mg n=34, least squares mean = ‐0.6 (SD 2.9); not significant		Tolcapone 200mg n=31 least‐squares mean = ‐1.4 (SD 2.8); not significant	Tolcapone 400mg n=31, least squares mean = ‐1.5 (SD 2.8); not significant
Rajput 1997	'On' state. Placebo n=66, mean = ‐0.3 (SD 4.1)			Tolcapone 100mg n=69, mean =‐0.8 (SD 3.3); not significant	Tolcapone 200mg n=67 mean = 0.2 (SD 3.3); not significant